Table 1 Study participants characteristics (n = 97)
Factor | Â | n (%) |
|---|---|---|
Sex | Male | 30 (31%) |
Female | 67 (69%) | |
Age | Mean (s.d.) | 36 (8) |
WHO HIV stage | 1 | 3 (3%) |
2 | 34 (35%) | |
3 | 54 (56%) | |
4 | 6 (6%) | |
CD4 cells (cells/ul) | <50 | 22 (23%) |
50–99 | 19 (19%) | |
100–149 | 24 (25%) | |
150–199 | 32 (33%) | |
Main study treatment arm | Median (IQR) | 120 (58–163) |
Fluconazole | 47 (48%) | |
Placebo | 50 (52%) | |
Anti-retroviral treatment backbone (missing = 2) | AZT/3TC | 77 (81%) |
D4T/3TC | 16 (17%) | |
Truvada | 2 (2%) | |
Non-nucleoside reverse-transcriptase inhibitors (missing = 1) | Nevirapine | 70 (73%) |
Efavirenz | 26 (27%) | |
Died during study | No | 88 (91%) |
Yes | 9 (9%) |